Neuland Laboratories Limited

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, SUNPHARMA.BO has a market cap of 4.4T. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while SUNPHARMA.BO trades at ₹1,820.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas SUNPHARMA.BO's P/E ratio is 40.09. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check SUNPHARMA.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, SUNPHARMA.NS has a market cap of 4.4T. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while SUNPHARMA.NS trades at ₹1,820.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas SUNPHARMA.NS's P/E ratio is 40.02. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check SUNPHARMA.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, DIVISLAB.NS has a market cap of 1.8T. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while DIVISLAB.NS trades at ₹6,651.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas DIVISLAB.NS's P/E ratio is 70.69. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check DIVISLAB.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, DIVISLAB.BO has a market cap of 1.8T. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while DIVISLAB.BO trades at ₹6,653.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas DIVISLAB.BO's P/E ratio is 70.65. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check DIVISLAB.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, TORNTPHARM.BO has a market cap of 1.4T. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while TORNTPHARM.BO trades at ₹4,275.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas TORNTPHARM.BO's P/E ratio is 67.23. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to TORNTPHARM.BO's ROE of +0.29%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check TORNTPHARM.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, TORNTPHARM.NS has a market cap of 1.4T. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while TORNTPHARM.NS trades at ₹4,275.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas TORNTPHARM.NS's P/E ratio is 63.50. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to TORNTPHARM.NS's ROE of +0.29%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check TORNTPHARM.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, LUPIN.BO has a market cap of 1.1T. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while LUPIN.BO trades at ₹2,343.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas LUPIN.BO's P/E ratio is 24.91. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to LUPIN.BO's ROE of +0.27%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check LUPIN.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, LUPIN.NS has a market cap of 1.1T. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while LUPIN.NS trades at ₹2,343.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas LUPIN.NS's P/E ratio is 23.16. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to LUPIN.NS's ROE of +0.27%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check LUPIN.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while DRREDDY.BO trades at ₹1,270.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas DRREDDY.BO's P/E ratio is 18.99. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to DRREDDY.BO's ROE of +0.16%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check DRREDDY.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while DRREDDY.NS trades at ₹1,271.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas DRREDDY.NS's P/E ratio is 18.97. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to DRREDDY.NS's ROE of +0.16%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check DRREDDY.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, MANKIND.BO has a market cap of 933.2B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while MANKIND.BO trades at ₹2,320.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas MANKIND.BO's P/E ratio is 52.41. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to MANKIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check MANKIND.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, MANKIND.NS has a market cap of 932.1B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while MANKIND.NS trades at ₹2,319.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas MANKIND.NS's P/E ratio is 52.34. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to MANKIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check MANKIND.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, ZYDUSLIFE.NS has a market cap of 908B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while ZYDUSLIFE.NS trades at ₹912.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas ZYDUSLIFE.NS's P/E ratio is 18.40. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check ZYDUSLIFE.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, ZYDUSLIFE.BO has a market cap of 907.3B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while ZYDUSLIFE.BO trades at ₹911.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas ZYDUSLIFE.BO's P/E ratio is 18.39. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check ZYDUSLIFE.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, AUROPHARMA.NS has a market cap of 799.2B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while AUROPHARMA.NS trades at ₹1,428.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas AUROPHARMA.NS's P/E ratio is 22.92. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to AUROPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check AUROPHARMA.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, AUROPHARMA.BO has a market cap of 799.1B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while AUROPHARMA.BO trades at ₹1,428.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas AUROPHARMA.BO's P/E ratio is 23.36. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to AUROPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check AUROPHARMA.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, GLENMARK.NS has a market cap of 675.5B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while GLENMARK.NS trades at ₹2,417.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas GLENMARK.NS's P/E ratio is 63.36. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to GLENMARK.NS's ROE of +0.12%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to GLENMARK.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check GLENMARK.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, GLENMARK.BO has a market cap of 675.2B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while GLENMARK.BO trades at ₹2,420.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas GLENMARK.BO's P/E ratio is 63.35. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to GLENMARK.BO's ROE of +0.12%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to GLENMARK.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check GLENMARK.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, ALKEM.NS has a market cap of 640.9B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while ALKEM.NS trades at ₹5,403.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas ALKEM.NS's P/E ratio is 27.05. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to ALKEM.NS's ROE of +0.19%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check ALKEM.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, ALKEM.BO has a market cap of 640.3B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while ALKEM.BO trades at ₹5,397.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas ALKEM.BO's P/E ratio is 27.00. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to ALKEM.BO's ROE of +0.19%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check ALKEM.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, LAURUSLABS.BO has a market cap of 629.7B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while LAURUSLABS.BO trades at ₹1,164.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas LAURUSLABS.BO's P/E ratio is 74.73. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check LAURUSLABS.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, LAURUSLABS.NS has a market cap of 629.7B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while LAURUSLABS.NS trades at ₹1,164.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas LAURUSLABS.NS's P/E ratio is 74.63. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check LAURUSLABS.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while SUVENPHAR.NS trades at ₹1,078.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to SUVENPHAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check SUVENPHAR.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while SUVENPHAR.BO trades at ₹1,075.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to SUVENPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check SUVENPHAR.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, IPCALAB.BO has a market cap of 388.3B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while IPCALAB.BO trades at ₹1,543.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas IPCALAB.BO's P/E ratio is 42.72. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to IPCALAB.BO's ROE of +0.12%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to IPCALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check IPCALAB.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, IPCALAB.NS has a market cap of 388.2B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while IPCALAB.NS trades at ₹1,541.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas IPCALAB.NS's P/E ratio is 42.71. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to IPCALAB.NS's ROE of +0.12%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to IPCALAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check IPCALAB.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, AJANTPHARM.BO has a market cap of 362.8B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while AJANTPHARM.BO trades at ₹2,900.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas AJANTPHARM.BO's P/E ratio is 35.81. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check AJANTPHARM.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, AJANTPHARM.NS has a market cap of 362.4B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while AJANTPHARM.NS trades at ₹2,897.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas AJANTPHARM.NS's P/E ratio is 35.68. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check AJANTPHARM.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, EMCURE.NS has a market cap of 340B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while EMCURE.NS trades at ₹1,690.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas EMCURE.NS's P/E ratio is 39.09. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to EMCURE.NS's ROE of +0.19%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to EMCURE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check EMCURE.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, JBCHEPHARM.NS has a market cap of 334.3B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while JBCHEPHARM.NS trades at ₹2,094.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas JBCHEPHARM.NS's P/E ratio is 43.92. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to JBCHEPHARM.NS's ROE of +0.22%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check JBCHEPHARM.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, JBCHEPHARM.BO has a market cap of 333.7B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while JBCHEPHARM.BO trades at ₹2,096.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas JBCHEPHARM.BO's P/E ratio is 43.74. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to JBCHEPHARM.BO's ROE of +0.22%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check JBCHEPHARM.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while PEL.NS trades at ₹1,124.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to PEL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check PEL.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, WOCKPHARMA.BO has a market cap of 231.6B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while WOCKPHARMA.BO trades at ₹1,537.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas WOCKPHARMA.BO's P/E ratio is 1131.35. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to WOCKPHARMA.BO's ROE of +0.01%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to WOCKPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check WOCKPHARMA.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, WOCKPHARMA.NS has a market cap of 231.6B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while WOCKPHARMA.NS trades at ₹1,537.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas WOCKPHARMA.NS's P/E ratio is 1130.95. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to WOCKPHARMA.NS's ROE of +0.01%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to WOCKPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check WOCKPHARMA.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, PPLPHARMA.BO has a market cap of 212.1B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while PPLPHARMA.BO trades at ₹159.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas PPLPHARMA.BO's P/E ratio is -65.16. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check PPLPHARMA.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, NEULANDLAB.NS has a market cap of 206.9B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while NEULANDLAB.NS trades at ₹16,204.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas NEULANDLAB.NS's P/E ratio is 115.56. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to NEULANDLAB.NS's ROE of +0.12%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to NEULANDLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check NEULANDLAB.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, ASTRAZEN.BO has a market cap of 201.2B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while ASTRAZEN.BO trades at ₹8,233.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas ASTRAZEN.BO's P/E ratio is 99.92. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to ASTRAZEN.BO's ROE of +0.27%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check ASTRAZEN.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, ASTRAZEN.NS has a market cap of 201.2B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while ASTRAZEN.NS trades at ₹8,228.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas ASTRAZEN.NS's P/E ratio is 99.96. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to ASTRAZEN.NS's ROE of +0.27%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to ASTRAZEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check ASTRAZEN.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, NATCOPHARM.NS has a market cap of 199.6B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while NATCOPHARM.NS trades at ₹1,125.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas NATCOPHARM.NS's P/E ratio is 12.83. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to NATCOPHARM.NS's ROE of +0.20%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to NATCOPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check NATCOPHARM.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, NATCOPHARM.BO has a market cap of 199.5B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while NATCOPHARM.BO trades at ₹1,124.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas NATCOPHARM.BO's P/E ratio is 12.96. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to NATCOPHARM.BO's ROE of +0.20%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check NATCOPHARM.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, ERIS.BO has a market cap of 187.6B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while ERIS.BO trades at ₹1,357.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas ERIS.BO's P/E ratio is 42.84. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to ERIS.BO's ROE of +0.14%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check ERIS.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, ERIS.NS has a market cap of 187.5B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while ERIS.NS trades at ₹1,358.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas ERIS.NS's P/E ratio is 42.99. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to ERIS.NS's ROE of +0.14%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check ERIS.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, COHANCE.NS has a market cap of 180.1B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while COHANCE.NS trades at ₹454.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas COHANCE.NS's P/E ratio is 92.85. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to COHANCE.NS's ROE of +0.09%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to COHANCE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check COHANCE.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, COHANCE.BO has a market cap of 179.8B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while COHANCE.BO trades at ₹454.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas COHANCE.BO's P/E ratio is 92.69. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to COHANCE.BO's ROE of +0.09%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to COHANCE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check COHANCE.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, GRANULES.NS has a market cap of 174.3B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while GRANULES.NS trades at ₹711.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas GRANULES.NS's P/E ratio is 28.72. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check GRANULES.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, GRANULES.BO has a market cap of 170.7B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while GRANULES.BO trades at ₹711.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas GRANULES.BO's P/E ratio is 31.28. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check GRANULES.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, APLLTD.NS has a market cap of 150.5B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while APLLTD.NS trades at ₹769.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas APLLTD.NS's P/E ratio is 23.86. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to APLLTD.NS's ROE of +0.12%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check APLLTD.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, APLLTD.BO has a market cap of 150.4B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while APLLTD.BO trades at ₹768.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas APLLTD.BO's P/E ratio is 23.85. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to APLLTD.BO's ROE of +0.12%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check APLLTD.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, JUBLPHARMA.NS has a market cap of 147.5B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while JUBLPHARMA.NS trades at ₹940.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas JUBLPHARMA.NS's P/E ratio is 34.19. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to JUBLPHARMA.NS's ROE of +0.07%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to JUBLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check JUBLPHARMA.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, JUBLPHARMA.BO has a market cap of 147.4B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while JUBLPHARMA.BO trades at ₹938.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas JUBLPHARMA.BO's P/E ratio is 34.14. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to JUBLPHARMA.BO's ROE of +0.07%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to JUBLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check JUBLPHARMA.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while GLS.NS trades at ₹1,086.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to GLS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check GLS.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while GLS.BO trades at ₹1,085.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to GLS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check GLS.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, CAPLIPOINT.NS has a market cap of 132B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while CAPLIPOINT.NS trades at ₹1,741.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas CAPLIPOINT.NS's P/E ratio is 21.57. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to CAPLIPOINT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check CAPLIPOINT.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, CAPLIPOINT.BO has a market cap of 131.9B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while CAPLIPOINT.BO trades at ₹1,741.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas CAPLIPOINT.BO's P/E ratio is 21.55. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, NEULANDLAB.BO and CAPLIPOINT.BO have similar daily volatility (2.64).Check CAPLIPOINT.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, ALIVUS.NS has a market cap of 131.2B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while ALIVUS.NS trades at ₹1,076.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas ALIVUS.NS's P/E ratio is 24.17. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to ALIVUS.NS's ROE of +0.19%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to ALIVUS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check ALIVUS.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, ALIVUS.BO has a market cap of 131.1B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while ALIVUS.BO trades at ₹1,074.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas ALIVUS.BO's P/E ratio is 24.16. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to ALIVUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check ALIVUS.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while CAPPL.BO trades at ₹1,446.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to CAPPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check CAPPL.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, STAR.NS has a market cap of 95.1B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while STAR.NS trades at ₹1,052.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas STAR.NS's P/E ratio is 18.60. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to STAR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check STAR.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, STAR.BO has a market cap of 95.1B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while STAR.BO trades at ₹1,050.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas STAR.BO's P/E ratio is 18.60. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to STAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check STAR.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, VIYASH.NS has a market cap of 89.4B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while VIYASH.NS trades at ₹200.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas VIYASH.NS's P/E ratio is 79.07. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to VIYASH.NS's ROE of +0.10%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to VIYASH.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check VIYASH.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, AKUMS.NS has a market cap of 85.6B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while AKUMS.NS trades at ₹552.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas AKUMS.NS's P/E ratio is 26.74. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to AKUMS.NS's ROE of +0.10%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check AKUMS.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, PGHL.NS has a market cap of 85.5B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while PGHL.NS trades at ₹5,173.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas PGHL.NS's P/E ratio is 36.17. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to PGHL.NS's ROE of +0.51%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check PGHL.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, PGHL.BO has a market cap of 85.5B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while PGHL.BO trades at ₹5,160.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas PGHL.BO's P/E ratio is 36.19. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to PGHL.BO's ROE of +0.51%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check PGHL.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, SHILPAMED.NS has a market cap of 81.9B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while SHILPAMED.NS trades at ₹424.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas SHILPAMED.NS's P/E ratio is 37.05. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to SHILPAMED.NS's ROE of +0.06%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to SHILPAMED.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check SHILPAMED.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, SUDEEPPHRM.NS has a market cap of 77.9B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while SUDEEPPHRM.NS trades at ₹686.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas SUDEEPPHRM.NS's P/E ratio is 46.43. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to SUDEEPPHRM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check SUDEEPPHRM.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, AARTIPHARM.NS has a market cap of 73.1B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while AARTIPHARM.NS trades at ₹767.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas AARTIPHARM.NS's P/E ratio is 34.24. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to AARTIPHARM.NS's ROE of +0.11%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to AARTIPHARM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check AARTIPHARM.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, AARTIPHARM.BO has a market cap of 73B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while AARTIPHARM.BO trades at ₹771.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas AARTIPHARM.BO's P/E ratio is 34.15. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to AARTIPHARM.BO's ROE of +0.11%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to AARTIPHARM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check AARTIPHARM.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, FDC.BO has a market cap of 60.6B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while FDC.BO trades at ₹368.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas FDC.BO's P/E ratio is 27.95. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to FDC.BO's ROE of +0.09%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to FDC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check FDC.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, FDC.NS has a market cap of 60.5B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while FDC.NS trades at ₹368.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas FDC.NS's P/E ratio is 27.96. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to FDC.NS's ROE of +0.09%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to FDC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check FDC.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while SEQUENT.NS trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to SEQUENT.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check SEQUENT.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while SEQUENT.BO trades at ₹202.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to SEQUENT.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check SEQUENT.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, SUVEN.BO has a market cap of 49.3B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while SUVEN.BO trades at ₹205.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas SUVEN.BO's P/E ratio is -17.28. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to SUVEN.BO's ROE of -1.58%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to SUVEN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check SUVEN.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, INNOVACAP.NS has a market cap of 48.3B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while INNOVACAP.NS trades at ₹871.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas INNOVACAP.NS's P/E ratio is 36.46. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to INNOVACAP.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check INNOVACAP.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, SUVEN.NS has a market cap of 47.6B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while SUVEN.NS trades at ₹205.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas SUVEN.NS's P/E ratio is -17.26. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to SUVEN.NS's ROE of -1.58%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to SUVEN.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check SUVEN.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, SPARC.BO has a market cap of 45.4B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while SPARC.BO trades at ₹140.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas SPARC.BO's P/E ratio is -16.92. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to SPARC.BO's ROE of +1.25%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to SPARC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check SPARC.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, SPARC.NS has a market cap of 45.3B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while SPARC.NS trades at ₹140.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas SPARC.NS's P/E ratio is -16.93. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to SPARC.NS's ROE of +1.25%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to SPARC.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check SPARC.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, SHILPAMED.BO has a market cap of 40.9B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while SHILPAMED.BO trades at ₹424.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas SHILPAMED.BO's P/E ratio is 37.02. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to SHILPAMED.BO's ROE of +0.06%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to SHILPAMED.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check SHILPAMED.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, GUJTHEM.NS has a market cap of 40.6B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while GUJTHEM.NS trades at ₹382.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas GUJTHEM.NS's P/E ratio is 84.61. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to GUJTHEM.NS's ROE of +0.19%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to GUJTHEM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check GUJTHEM.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, RPGLIFE.BO has a market cap of 40.1B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while RPGLIFE.BO trades at ₹2,320.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas RPGLIFE.BO's P/E ratio is 19.79. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to RPGLIFE.BO's ROE of +0.41%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to RPGLIFE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check RPGLIFE.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, RPGLIFE.NS has a market cap of 40B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while RPGLIFE.NS trades at ₹2,322.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas RPGLIFE.NS's P/E ratio is 19.72. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to RPGLIFE.NS's ROE of +0.41%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to RPGLIFE.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check RPGLIFE.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, AARTIDRUGS.NS has a market cap of 36.1B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while AARTIDRUGS.NS trades at ₹391.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas AARTIDRUGS.NS's P/E ratio is 17.89. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to AARTIDRUGS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check AARTIDRUGS.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, AARTIDRUGS.BO has a market cap of 36B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while AARTIDRUGS.BO trades at ₹390.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas AARTIDRUGS.BO's P/E ratio is 17.84. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to AARTIDRUGS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check AARTIDRUGS.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, ORCHPHARMA.NS has a market cap of 31.9B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while ORCHPHARMA.NS trades at ₹627.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas ORCHPHARMA.NS's P/E ratio is 167.79. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to ORCHPHARMA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check ORCHPHARMA.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, ORCHPHARMA.BO has a market cap of 31.9B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while ORCHPHARMA.BO trades at ₹625.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas ORCHPHARMA.BO's P/E ratio is 166.82. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to ORCHPHARMA.BO's ROE of +0.00%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to ORCHPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check ORCHPHARMA.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, GUFICBIO.BO has a market cap of 29.3B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while GUFICBIO.BO trades at ₹287.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas GUFICBIO.BO's P/E ratio is 58.59. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to GUFICBIO.BO's ROE of +0.08%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to GUFICBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check GUFICBIO.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, GUFICBIO.NS has a market cap of 29.3B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while GUFICBIO.NS trades at ₹287.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas GUFICBIO.NS's P/E ratio is 58.68. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to GUFICBIO.NS's ROE of +0.08%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to GUFICBIO.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check GUFICBIO.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, BLISSGVS.BO has a market cap of 29B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while BLISSGVS.BO trades at ₹269.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas BLISSGVS.BO's P/E ratio is 26.93. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to BLISSGVS.BO's ROE of +0.10%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to BLISSGVS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check BLISSGVS.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, BLISSGVS.NS has a market cap of 29B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while BLISSGVS.NS trades at ₹269.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas BLISSGVS.NS's P/E ratio is 26.93. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to BLISSGVS.NS's ROE of +0.10%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to BLISSGVS.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check BLISSGVS.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, IOLCP.NS has a market cap of 27.9B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while IOLCP.NS trades at ₹94.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas IOLCP.NS's P/E ratio is 24.05. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to IOLCP.NS's ROE of +0.07%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to IOLCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check IOLCP.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, IOLCP.BO has a market cap of 27.9B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while IOLCP.BO trades at ₹94.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas IOLCP.BO's P/E ratio is 24.04. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to IOLCP.BO's ROE of +0.07%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to IOLCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check IOLCP.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, UNICHEMLAB.BO has a market cap of 27.1B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while UNICHEMLAB.BO trades at ₹376.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas UNICHEMLAB.BO's P/E ratio is 9.23. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to UNICHEMLAB.BO's ROE of +0.12%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to UNICHEMLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check UNICHEMLAB.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, UNICHEMLAB.NS has a market cap of 27.1B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while UNICHEMLAB.NS trades at ₹377.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas UNICHEMLAB.NS's P/E ratio is 9.21. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to UNICHEMLAB.NS's ROE of +0.12%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to UNICHEMLAB.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check UNICHEMLAB.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, NOVARTIND.NS has a market cap of 25.3B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while NOVARTIND.NS trades at ₹1,036.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas NOVARTIND.NS's P/E ratio is 26.07. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to NOVARTIND.NS's ROE of +0.13%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to NOVARTIND.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check NOVARTIND.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, NOVARTIND.BO has a market cap of 25.2B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while NOVARTIND.BO trades at ₹1,038.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas NOVARTIND.BO's P/E ratio is 25.97. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to NOVARTIND.BO's ROE of +0.13%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to NOVARTIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check NOVARTIND.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, SOLARA.NS has a market cap of 25B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while SOLARA.NS trades at ₹501.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas SOLARA.NS's P/E ratio is -107.89. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to SOLARA.NS's ROE of -0.02%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check SOLARA.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, SOLARA.BO has a market cap of 25B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while SOLARA.BO trades at ₹501.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas SOLARA.BO's P/E ratio is -108.23. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to SOLARA.BO's ROE of -0.02%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to SOLARA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check SOLARA.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, HIKAL.NS has a market cap of 24B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while HIKAL.NS trades at ₹197.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas HIKAL.NS's P/E ratio is -183.70. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to HIKAL.NS's ROE of -0.01%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to HIKAL.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check HIKAL.NS's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, HIKAL.BO has a market cap of 24B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while HIKAL.BO trades at ₹196.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas HIKAL.BO's P/E ratio is 243.31. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to HIKAL.BO's ROE of -0.01%. Regarding short-term risk, NEULANDLAB.BO is more volatile compared to HIKAL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check HIKAL.BO's competition here

NEULANDLAB.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NEULANDLAB.BO stands at 207B. In comparison, ALEMBICLTD.NS has a market cap of 23.5B. Regarding current trading prices, NEULANDLAB.BO is priced at ₹16,203.05, while ALEMBICLTD.NS trades at ₹91.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NEULANDLAB.BO currently has a P/E ratio of 115.68, whereas ALEMBICLTD.NS's P/E ratio is 7.37. In terms of profitability, NEULANDLAB.BO's ROE is +0.12%, compared to ALEMBICLTD.NS's ROE of +0.13%. Regarding short-term risk, NEULANDLAB.BO is less volatile compared to ALEMBICLTD.NS. This indicates potentially lower risk in terms of short-term price fluctuations for NEULANDLAB.BO.Check ALEMBICLTD.NS's competition here